Adolor Corporation, a biopharmaceutical company working in the pain management area, has one drug under FDA Phase I start-up study and one in final Phase II approvals consideration. “Promising” is the general word that most are currently using for the Phase II Entereg product. It is expecting further responses from the FDA on January 23d. A phase I Delta agonist product has been granted the go ahead for trials to begin in the first quarter of 2008.
Currently, the short term prognosis for the Entereg product is thought to be good where approvals are concerned. Some, however, are a bit more pessimistic about the approvals process as the testing comparisons between test users and placebo were so similar and the follow up procedure so limited. Ultimately, the drug does appear to show signs that it reduces hospital stays by one day and gastrointestinal pain in the upper and lower areas. Currently, there is a bit of a betting/guessing game going on about the drug’s final outcome. As a biotechnology’s stock price is, generally, predicated on its pipeline and approvals, this outcome is fairly important. January 23d will tell quite a bit.
Perhaps more important , with regard to the company’s pipeline, is a Novel delta agonist which works to affect pain receptors related to inflammation and possibly other disease applications. The importance of this particular pipeline application is that the FDA has not approved any other Delta agonists for use in these areas. The company appears to have a stable handler in Pfizer and a solid grasp on its research and development programs dealing with pain. It is one of those biotechnology companies that plays for the long term win in the medications marketplace.
Let us hear your thoughts below:
